[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20004946L - Humanisert antistoff mot human vevsfaktor (TF) og fremgangsmåte ved fremstilling av det humaniserte antistoff - Google Patents

Humanisert antistoff mot human vevsfaktor (TF) og fremgangsmåte ved fremstilling av det humaniserte antistoff

Info

Publication number
NO20004946L
NO20004946L NO20004946A NO20004946A NO20004946L NO 20004946 L NO20004946 L NO 20004946L NO 20004946 A NO20004946 A NO 20004946A NO 20004946 A NO20004946 A NO 20004946A NO 20004946 L NO20004946 L NO 20004946L
Authority
NO
Norway
Prior art keywords
chain
humanized antibody
region
humanized
antibody
Prior art date
Application number
NO20004946A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004946D0 (no
Inventor
Koh Sato
Hideki Adachi
Naohiro Yabuta
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20004946D0 publication Critical patent/NO20004946D0/no
Publication of NO20004946L publication Critical patent/NO20004946L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20004946A 1998-04-03 2000-10-02 Humanisert antistoff mot human vevsfaktor (TF) og fremgangsmåte ved fremstilling av det humaniserte antistoff NO20004946L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9185098 1998-04-03
PCT/JP1999/001768 WO1999051743A1 (fr) 1998-04-03 1999-04-02 Anticorps humanise contre le facteur tissulaire humain (tf) et procede de production d'anticorps humanises

Publications (2)

Publication Number Publication Date
NO20004946D0 NO20004946D0 (no) 2000-10-02
NO20004946L true NO20004946L (no) 2000-12-04

Family

ID=14038058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004946A NO20004946L (no) 1998-04-03 2000-10-02 Humanisert antistoff mot human vevsfaktor (TF) og fremgangsmåte ved fremstilling av det humaniserte antistoff

Country Status (19)

Country Link
US (2) US6677436B1 (ja)
EP (2) EP1069185B1 (ja)
JP (2) JP3998419B2 (ja)
KR (1) KR20010042435A (ja)
CN (1) CN1303431A (ja)
AT (1) ATE512225T1 (ja)
AU (1) AU752730B2 (ja)
BR (1) BR9909382A (ja)
CA (1) CA2325346A1 (ja)
DK (1) DK1069185T3 (ja)
ES (1) ES2364266T3 (ja)
HU (1) HUP0101160A2 (ja)
IL (1) IL138801A0 (ja)
NO (1) NO20004946L (ja)
PL (1) PL343322A1 (ja)
PT (1) PT1069185E (ja)
SK (1) SK14812000A3 (ja)
TR (2) TR200002885T2 (ja)
WO (1) WO1999051743A1 (ja)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716282B2 (en) 1995-06-07 2000-02-24 Johnson & Johnson Research Pty. Limited CDR-grafted anti-tissue factor antibodies and methods of use thereof
US6703197B1 (en) * 1996-11-27 2004-03-09 Martinex R&D, Inc. Human methionine synthase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7764130B2 (en) * 1999-01-22 2010-07-27 Multigig Inc. Electronic circuitry
IL148980A0 (en) * 1999-10-01 2002-11-10 Chugai Pharmaceutical Co Ltd An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
DE19962583A1 (de) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad Antikörper gegen Plasmazellen
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
JP2003527861A (ja) * 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
JP4391086B2 (ja) 2001-03-09 2009-12-24 中外製薬株式会社 タンパク質精製方法
EP1374896A4 (en) * 2001-03-26 2005-04-06 Koji Suzuki MEANS TO IMPROVE THE FLUID CHARACTERISTICS OF BLOOD
WO2003018056A1 (fr) * 2001-08-29 2003-03-06 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
RU2004113373A (ru) * 2001-10-02 2005-03-27 Ново Нордиск А/С (DK) Антитела против человеческого тканевого фактора
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
DE60334538D1 (de) * 2002-05-01 2010-11-25 Bayer Schering Pharma Ag Neue gegen den gewebefaktor gerichtete thrombomodulin-fusionsproteine als antikoagulantien
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
AU2003242430A1 (en) * 2002-05-23 2003-12-12 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
JP4489591B2 (ja) 2002-08-27 2010-06-23 中外製薬株式会社 タンパク質溶液製剤の安定化方法
KR101119448B1 (ko) 2002-09-11 2012-03-15 추가이 세이야쿠 가부시키가이샤 단백질 정제 방법
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
WO2004068931A2 (en) * 2003-02-07 2004-08-19 Protein Design Labs Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
CN100353997C (zh) * 2003-02-28 2007-12-12 中外制药株式会社 稳定的含蛋白质的制剂
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US20050031615A1 (en) * 2003-05-30 2005-02-10 Anderson G. Mark Method of inhibiting tumor growth with anti-tissue factor antibodies
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
CN1863556B (zh) * 2003-06-19 2012-05-16 吉宁特有限公司 用于治疗凝血相关紊乱的组合物和方法
CA2542372A1 (en) * 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP2311945A1 (en) 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies substituting for functional proteins
LT2348051T (lt) * 2003-11-05 2019-02-25 Roche Glycart Ag Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija
AU2005291486A1 (en) 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
CA2601858A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP2824183B1 (en) 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing bispecific antibodies
MX2007013924A (es) * 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
SG192479A1 (en) * 2005-08-26 2013-08-30 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
WO2008140571A2 (en) * 2006-11-15 2008-11-20 Functional Genetics, Inc. Methods and compositions for treating influenza
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
EP4339294A3 (en) 2007-09-26 2024-10-16 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
MY163473A (en) 2007-09-26 2017-09-15 Chugai Pharmaceutical Co Ltd Modified antibody constant region
US20110129459A1 (en) 2007-12-05 2011-06-02 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
KR101609894B1 (ko) * 2008-03-14 2016-04-08 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
HUE028589T2 (en) 2008-07-10 2016-12-28 Toray Industries Pharmaceutical preparation for the treatment and prevention of cancer
US9416192B2 (en) 2008-08-05 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5780762B2 (ja) 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
AR076875A1 (es) 2009-05-15 2011-07-13 Chugai Pharmaceutical Co Ltd Anticuerpo contra receptor de la tirosina quinasa (anti-axl)
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
CN101717447B (zh) * 2009-12-17 2012-06-27 山西省生物研究所 一种抗人重组组织因子单克隆抗体的制备方法
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
DK2532364T3 (en) 2010-02-04 2016-08-15 Toray Industries PHARMACEUTICAL COMPOSITION CONTAINING ANTI CAPRIN-1 ANTIBODIES FOR TREATMENT AND / OR PREVENTION OF CANCER
CA2788715C (en) 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP5742713B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP2532743B1 (en) 2010-02-04 2015-04-15 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
RS56599B1 (sr) 2010-06-15 2018-02-28 Genmab As Konjugati humanog antitela sa lekom protiv tkivnog faktora
US9334331B2 (en) 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
JP6032818B2 (ja) 2011-02-25 2016-11-30 中外製薬株式会社 ＦｃγＲＩＩｂ特異的Ｆｃ抗体
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
EP2735315B1 (en) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Stable protein-containing preparation containing argininamide or valinamide
AU2012290952B2 (en) 2011-08-04 2016-05-05 Toray Industries, Inc. Cancer treatment and/or prevention drug composition
CA2844030C (en) 2011-08-04 2019-09-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
CA2844040C (en) 2011-08-04 2019-05-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
CA2847302C (en) 2011-09-01 2021-02-16 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
PT2818481T (pt) 2012-02-21 2019-10-25 Toray Industries Composição farmacêutica para tratamento e/ou prevenção de cancro
IN2014KN01715A (ja) 2012-02-21 2015-10-23 Toray Industries
WO2013125640A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112014021101A2 (pt) 2012-02-21 2022-03-22 Toray Industries Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
WO2013147169A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
BR112014024209A2 (pt) 2012-03-30 2018-04-10 Toray Industries composição farmacêutica, agente farmacêutico e método de tratamento e/ou prevenção de cancêr da vesicula biliar
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
WO2014050926A1 (ja) 2012-09-28 2014-04-03 中外製薬株式会社 血液凝固反応の評価方法
CN105452294B (zh) 2013-08-09 2019-08-02 东丽株式会社 癌的治疗和/或预防用药物组合物
DK3050896T3 (da) 2013-09-27 2021-07-19 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
MX2016008498A (es) 2013-12-27 2016-10-07 Chugai Pharmaceutical Co Ltd Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
US10538591B2 (en) 2014-03-10 2020-01-21 The Brigham And Women's Hospital, Inc. Anti-fibulin-3 antibodies and uses thereof
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
EP3185004A4 (en) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
CA2959821A1 (en) * 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
TWI779010B (zh) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
ES2899894T3 (es) 2014-12-19 2022-03-15 Chugai Pharmaceutical Co Ltd Anticuerpos anti-C5 y métodos de uso
KR20240090831A (ko) 2015-02-05 2024-06-21 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
SG11201705093UA (en) 2015-02-27 2017-07-28 Chugai Pharmaceutical Co Ltd Composition for treating il-6-related diseases
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CN107454906B (zh) 2015-04-17 2022-05-27 豪夫迈·罗氏有限公司 使用凝固因子和多特异性抗体的联合治疗
US10988543B2 (en) 2015-11-11 2021-04-27 Opi Vi—Ip Holdco Llc Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
WO2017115773A1 (ja) 2015-12-28 2017-07-06 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
EP3437656A4 (en) 2016-03-28 2019-11-13 Toray Industries, Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
SG11201901961SA (en) 2016-09-06 2019-04-29 Chugai Pharmaceutical Co Ltd Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
KR20240005247A (ko) 2016-10-28 2024-01-11 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
US20200109390A1 (en) 2017-04-27 2020-04-09 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
TW201922796A (zh) 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
CA3083345A1 (en) * 2017-11-27 2019-05-31 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
SG11202006400UA (en) 2018-01-04 2020-08-28 Iconic Therapeutics Inc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
BR112020019935A2 (pt) 2018-03-30 2021-01-26 Toray Industries, Inc. medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer
TWI840360B (zh) 2018-05-21 2024-05-01 日商中外製藥股份有限公司 密封於玻璃容器之凍結乾燥的製劑、套組、製造凍結乾燥製劑的方法、防止或減低凍結乾燥製劑的玻璃容器成霧的方法、及容器內面經過硫酸銨處理或ｖｉｓｔ處理之玻璃容器
CN112243423B (zh) 2018-05-28 2022-11-04 中外制药株式会社 填充喷嘴
EP3956027A1 (en) 2019-04-18 2022-02-23 AC Immune SA Novel molecules for therapy and diagnosis
WO2021110995A1 (en) 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
JPWO2021182573A1 (ja) 2020-03-12 2021-09-16
CA3175277A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2021182572A1 (ja) 2020-03-12 2021-09-16
US20230165957A1 (en) 2020-03-12 2023-06-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
BR112022018161A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
JP2023525060A (ja) 2020-05-14 2023-06-14 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ２５抗体、その抗原結合断片及びその医薬用途
CN115667515A (zh) 2020-05-22 2023-01-31 中外制药株式会社 中和具有凝血因子viii(f.viii)功能替代活性的物质的抗体
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
JP2024500115A (ja) 2020-12-18 2024-01-04 エイシー イミューン ソシエテ アノニム 抗体デリバリー
EP4360648A1 (en) 2021-06-23 2024-05-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022298240A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240042415A (ko) 2021-07-27 2024-04-02 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4378478A1 (en) 2021-07-27 2024-06-05 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2023008459A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
MX2024004117A (es) 2021-10-08 2024-04-19 Chugai Pharmaceutical Co Ltd Metodo para preparar formulacion de jeringa precargada.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
HU218140B (hu) 1991-04-25 2000-06-28 Chugai Seiyaku Kabushiki Kaisha Humán interleukin-6-receptorral szembeni átalakított humán antitest
AU5093593A (en) * 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU716282B2 (en) 1995-06-07 2000-02-24 Johnson & Johnson Research Pty. Limited CDR-grafted anti-tissue factor antibodies and methods of use thereof

Also Published As

Publication number Publication date
CA2325346A1 (en) 1999-10-14
JP2008161198A (ja) 2008-07-17
BR9909382A (pt) 2000-12-05
EP1069185A1 (en) 2001-01-17
CN1303431A (zh) 2001-07-11
EP2363484A2 (en) 2011-09-07
HUP0101160A2 (hu) 2001-08-28
US7494647B2 (en) 2009-02-24
ES2364266T3 (es) 2011-08-30
NO20004946D0 (no) 2000-10-02
JP4180106B2 (ja) 2008-11-12
EP1069185A4 (en) 2005-01-19
AU752730B2 (en) 2002-09-26
AU3055699A (en) 1999-10-25
PT1069185E (pt) 2011-08-11
DK1069185T3 (da) 2011-06-27
US20040044187A1 (en) 2004-03-04
JP3998419B2 (ja) 2007-10-24
WO1999051743A1 (fr) 1999-10-14
EP1069185B1 (en) 2011-06-08
TR200101541T2 (tr) 2002-06-21
PL343322A1 (en) 2001-08-13
ATE512225T1 (de) 2011-06-15
IL138801A0 (en) 2001-10-31
SK14812000A3 (sk) 2001-08-06
KR20010042435A (ko) 2001-05-25
TR200002885T2 (tr) 2000-12-21
US6677436B1 (en) 2004-01-13
EP2363484A3 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
NO20004946L (no) Humanisert antistoff mot human vevsfaktor (TF) og fremgangsmåte ved fremstilling av det humaniserte antistoff
AU2936395A (en) Reconstituted human antibody against human interleukin-8
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DK0671927T3 (da) Neutraliserende humane monoklonale antistoffer mod respiratorisk syncytialvirus
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
ATE180511T1 (de) Humanisierter b-b10, ein anti-il-2-rezeptor- antikörper
EP0791359A4 (en) MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES
LU92912I2 (fr) Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala)
NO970221L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
NZ596723A (en) Human antibodies that bind human il-12 and methods for producing
ATE442859T1 (de) Monoclonaler anti-heparanase antikörper zur neutralisierung der heparanaseaktivität
ES2147365T3 (es) Un procedimiento para la preparacion del factor ix a partir de muestras biologicas.
ES2061655T3 (es) Un procedimiento para cultivar un hibridoma humano/humano productor de anticuerpos monoclonales humanos.
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
UA91182C2 (ru) Антитело, которое специфично связывается с фактором роста соединительной ткани (ctgf)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application